Skip to content

Application of cfDNA combined with protein marker liquid biopsy in early liver cancer screening in high-risk hepatitis B population

Preliminary exploration of the application of multi-omics liquid biopsy method M2P-HCC in early liver cancer screening in high-risk groups of hepatitis B-related liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061354
Enrollment
Unknown
Registered
2022-06-21
Start date
2022-06-10
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV-related liver cancer

Interventions

Case series:None

Sponsors

Infectious Disease Center, West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Age =18 years old and <80 years old; (2) Meet the diagnostic criteria for hepatitis B cirrhosis, with or without liver imaging examinations indicating liver nodules; (3) Meet the diagnostic criteria for chronic viral hepatitis B and liver imaging The medical examination showed liver nodules; (4) The patients signed the informed consent and were willing to follow the requirements of this study for regular follow-up review. If one of the second or third items is met, it can be included.

Exclusion criteria

Exclusion criteria: (1) Age 80 years old; (2) Patients who have been diagnosed with HCC or other malignant tumors in the past; (3) Patients infected with human immunodeficiency virus; (4) Combined autoimmune diseases (such as (5) Patients with a history of blood transfusion within the past 3 months. Patients meeting any of the above criteria were excluded.

Design outcomes

Secondary

MeasureTime frame
Sensitivity of AFP combined with ultrasound for screening liver cancer;The specificity of AFP combined with ultrasonography in screening liver cancer;

Primary

MeasureTime frame
Sensitivity of M2P-HCC for liver cancer screening;Specificity of M2P-HCC for screening liver cancer;

Countries

China

Contacts

Public ContactXuezhong Lei

Infectious Disease Center, West China Hospital, Sichuan University

18980601317@163.com+86 18980601317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026